|
related topics |
{customer, product, revenue} |
{regulation, change, law} |
{competitive, industry, competition} |
{property, intellectual, protect} |
{product, liability, claim} |
{product, market, service} |
{personnel, key, retain} |
{capital, credit, financial} |
{operation, international, foreign} |
{stock, price, share} |
{stock, price, operating} |
{control, financial, internal} |
|
We face intense competition in many of our markets.
We are subject to significant competition from companies that are pursuing technologies and products that are similar to our technology and products.
We rely on suppliers, vendors and subcontractors.
Our customer base is concentrated, and a substantial portion of our sales are provided by just three customers.
Many of our current and potential customers are from the pharmaceutical and biotechnology industries and are subject to risks faced by those industries.
We have only one manufacturing facility.
We rely on our trade secrets to protect our technology.
We must continue our research and development efforts to maintain our competitiveness.
Our ability to continue planned operations is dependent upon access to financing under a credit facility with our commercial lender.
We may be subjected to increased government regulation which could affect our ability to sell our products outside of the United States.
We rely on our key management and technical personnel.
Our stock is listed on the OTC Bulletin Board and our stockholders may have limited liquidity.
Our quarterly revenues and stock performance are variable.
We allow our customers to lease some of our products and those leases may not turn into sales.
We may be subject to product liability claims from our customers or by persons harmed by our customers products.
Our international business operations expose us to a variety of risks.
Compliance with internal controls reporting requirements will increase our costs.
Future changes in financial accounting standards may adversely affect our reported results of operations.
If our accounting estimates are not correct, our financial results could be adversely affected.
Full 10-K form ▸
|
|
related documents |
723889--3/30/2006--MFIC_CORP |
723889--3/21/2008--MFIC_CORP |
46080--2/22/2006--HASBRO_INC |
46080--2/27/2008--HASBRO_INC |
723889--3/29/2010--MICROFLUIDICS_INTERNATIONAL_CORP |
887227--6/13/2007--CHOLESTECH_CORPORATION |
1004960--3/13/2006--CONNETICS_CORP |
46080--2/25/2009--HASBRO_INC |
715073--11/29/2007--WEGENER_CORP |
851205--2/14/2008--COGNEX_CORP |
851205--3/1/2006--COGNEX_CORP |
8146--4/13/2009--ASTRO_MED_INC_/NEW/ |
891288--3/29/2007--QUESTCOR_PHARMACEUTICALS_INC |
1057083--3/21/2008--PC_TEL_INC |
927003--2/20/2007--ADVANCED_ENERGY_INDUSTRIES_INC |
877212--2/28/2006--ZEBRA_TECHNOLOGIES_CORP/DE |
1004608--3/30/2007--PINNACLE_DATA_SYSTEMS_INC |
18937--2/26/2008--CERADYNE_INC |
715073--11/26/2008--WEGENER_CORP |
320121--5/23/2006--TELOS_CORP |
722313--3/9/2007--NORTECH_SYSTEMS_INC |
46080--2/24/2010--HASBRO_INC |
1003950--3/11/2010--PERFORMANCE_TECHNOLOGIES_INC_\DE\ |
1034670--2/23/2007--AUTOLIV_INC |
732026--9/17/2007--TRIO_TECH_INTERNATIONAL |
1025148--9/11/2006--MOBIUS_MANAGEMENT_SYSTEMS_INC |
1003113--3/16/2006--MOLECULAR_DEVICES_CORP |
24741--2/15/2008--CORNING_INC_/NY |
1019787--4/13/2009--PURADYN_FILTER_TECHNOLOGIES_INC |
851205--2/28/2007--COGNEX_CORP |
|